晚期NSCLC患者血清EGFR基因突变状态的测定及意义

背景与目的小分子酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）对于表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的肺癌患者显示出良好的治疗效果。本研究旨在探讨晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者血清EGFR基因突变状态与EGFR-TKIs疗效的关系。方法检测80例一线口服EGFR-TKIs晚期NSCLC患者血清EGFR基因的突变状态,对患者进行长期随访并评价治疗效果。结果 80例患者血清EGFR基因突变27例（33.8%）,其中外显子19缺失突变12例...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 16; no. 6; pp. 303 - 307
Main Author 马玲 刘莉 张涛 单莉
Format Journal Article
LanguageChinese
Published 新疆医科大学附属肿瘤医院肺内一科, 新疆,830011 2013
Subjects
疗效
肺肿瘤
血清
表皮生长因子受体
酪氨酸激酶抑制剂
血清
Tyrosine kinase inhibitor
酪氨酸激酶抑制剂
Serum
Efficacy
肺肿瘤
表皮生长因子受体
Epidermal growth factor receptor
疗效
Lung neoplasms
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2013.06.06

Cover

Abstract 背景与目的小分子酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）对于表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的肺癌患者显示出良好的治疗效果。本研究旨在探讨晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者血清EGFR基因突变状态与EGFR-TKIs疗效的关系。方法检测80例一线口服EGFR-TKIs晚期NSCLC患者血清EGFR基因的突变状态,对患者进行长期随访并评价治疗效果。结果 80例患者血清EGFR基因突变27例（33.8%）,其中外显子19缺失突变12例（44.4%）,外显子21点突变15例（55.6%）;血清EGFR基因突变患者的有效率（55.6%,15/27）高于野生型患者（17.0%,9/53）,差异具有统计学意义（χ2=0.370,P〈0.001）;血清EGFR基因突变患者中位无进展生存时间（progress free survival,PFS）明显长于野生型患者（9.8个月vs5.7个月,P=0.014）。结论血清EGFR基因突变患者一线口服EGFR-TKIs的疗效优于野生型患者,血清EGFR基因状态可为EGFR-TKIs的一线治疗提供有效依据。
AbstractList 背景与目的 小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)对于表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的肺癌患者显示出良好的治疗效果.本研究旨在探讨晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血清EGFR基因突变状态与EGFR-TKIs疗效的关系.方法 检测80例一线口服EGFR-TKIs晚期NSCLC患者血清EGFR基因的突变状态,对患者进行长期随访并评价治疗效果.结果 80例患者血清EGFR基因突变27例(33.8％),其中外显子19缺失突变12例(44.4％),外显子21点突变15例(5S.6％)；血清EGFR基因突变患者的有效率(55.6％,15/27)高于野生型患者(17.0％,9/53),差异具有统计学意义(x2=0.370,P＜0.001)；血清EGFR基因突变患者中位无进展生存时间(progress free survival,PFS)明显长于野生型患者(9.8个月vs 5.7个月,P=0.014).结论 血清EGFR基因突变患者一线口服EGFR-TKIs的疗效优于野生型患者,血清EGFR基因状态可为EGFR-TKIs的一线治疗提供有效依据.
背景与目的小分子酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）对于表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的肺癌患者显示出良好的治疗效果。本研究旨在探讨晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者血清EGFR基因突变状态与EGFR-TKIs疗效的关系。方法检测80例一线口服EGFR-TKIs晚期NSCLC患者血清EGFR基因的突变状态,对患者进行长期随访并评价治疗效果。结果 80例患者血清EGFR基因突变27例（33.8%）,其中外显子19缺失突变12例（44.4%）,外显子21点突变15例（55.6%）;血清EGFR基因突变患者的有效率（55.6%,15/27）高于野生型患者（17.0%,9/53）,差异具有统计学意义（χ2=0.370,P〈0.001）;血清EGFR基因突变患者中位无进展生存时间（progress free survival,PFS）明显长于野生型患者（9.8个月vs5.7个月,P=0.014）。结论血清EGFR基因突变患者一线口服EGFR-TKIs的疗效优于野生型患者,血清EGFR基因状态可为EGFR-TKIs的一线治疗提供有效依据。
Author 马玲 刘莉 张涛 单莉
AuthorAffiliation 新疆医科大学附属肿瘤医院肺内一科,新疆830011
AuthorAffiliation_xml – name: 新疆医科大学附属肿瘤医院肺内一科, 新疆,830011
Author_FL Li LIU
Tao ZHANG
Li SHAN
Ling MA
Author_FL_xml – sequence: 1
  fullname: Ling MA
– sequence: 2
  fullname: Li LIU
– sequence: 3
  fullname: Tao ZHANG
– sequence: 4
  fullname: Li SHAN
Author_xml – sequence: 1
  fullname: 马玲 刘莉 张涛 单莉
BookMark eNo1j0FLAkEAhYcwSK0fER067TazMzs7c4pY1IKloLzL7O6sKTWWS0SeVPSQHbyWBRbdOnQrqt_Tjv6MJix48N7h4z1eAeRUS0kANhC0sefxrabdSFNlIwi5hQnitgMRtiE1WgJ5xDm3KGJezuR_ZAUU0rQJIXU4Jnmwre8m-mG6f-QHvu4_z7vD-VNXfwxLlfJhNv3K7h9nL71sfDsbvetubzYZ6Leb7HWSjUd6MP7-vF4Fy4k4SeXanxdBtVyq-rtWcFDZ83cCK3IZtRISyohIHLJYkkhIxl1GKEKhgIy5ieNEknISc4-EEWbSc2GcEEwpjaXrxB7GRbC5qL0UKhGqXmu2LtrKDNY69UR0Or-_ITWvDLm-IKPjlqqfNwx71m6civZVzSwyhyGMfwCm-myz
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3779/j.issn.1009-3419.2013.06.06
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
DocumentTitle_FL Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
EISSN 1999-6187
EndPage 307
ExternalDocumentID zgfazz201306006
46182813
GrantInformation_xml – fundername: 新疆医科大学科研创新基金资助项目; 乌鲁木齐市科学技术计划项目; This study was supported by the grant from Xinjiang Medical Scientific Research Innovation Fund (to Ling MA); Urumqi Science and Technology Projects (to Ling MA)
  funderid: (XJC201032); (Y111310025); (XJC201032); (Y111310025)
GroupedDBID ---
-05
04C
29R
2B.
2C~
2RA
2WC
3V.
5GY
5VS
6PF
92F
92I
92L
AAWTL
ABUWG
ACGFS
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVBZV
C1A
CCEZO
CCPQU
CIEJG
CQIGP
CW9
DIK
E3Z
EBD
EIHBH
EMOBN
EOJEC
F5P
GROUPED_DOAJ
HYE
IPNFZ
KQ8
KWQ
OBODZ
OK1
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TCJ
TGQ
U1G
U5O
W91
~WA
4A8
93N
PGMZT
PHGZM
PHGZT
PMFND
PSX
ID FETCH-LOGICAL-c586-f4bec4e3b8de4cae89584611ba0885f22ce694d974bc38e750df43666de52d733
ISSN 1009-3419
IngestDate Thu May 29 03:56:17 EDT 2025
Wed Feb 14 10:43:18 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords 血清
Tyrosine kinase inhibitor
酪氨酸激酶抑制剂
Serum
Efficacy
肺肿瘤
表皮生长因子受体
Epidermal growth factor receptor
疗效
Lung neoplasms
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c586-f4bec4e3b8de4cae89584611ba0885f22ce694d974bc38e750df43666de52d733
Notes Ling MA, Li LIU, Tao ZHANG, Li SHAN（ Department of Medical Oncology, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China ）
Lung neoplasms; Serum; Epidermal growth factor receptor; Tyrosine kinase inhibitor; Efficacy
Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） has shown a high response rate in the treatment of lung cancer in patients with （EGFR） mutation. The aim of this study is to evaluate the relationship between EGFR mutation status in serum and predicting benefit from EGFR-TKIs therapy in patients with advanced non-small cell lung cancer （NSCLC）. Methods We examined EGFR mutation status in serum of 80 patients with advanced, EGFR-TKIs given as first-line therapy NSCLC. All patients were received long-term follow-up, and the drug efficacy were observed and evaluated. Results The EGFR mutation in serum was detected in 33.8% （27/80） of NSCLC patients examined, in which exon 19 deletion mutation was present at a frequency of 44.4% （
PageCount 5
ParticipantIDs wanfang_journals_zgfazz201306006
chongqing_primary_46182813
PublicationCentury 2000
PublicationDate 2013
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – year: 2013
  text: 2013
PublicationDecade 2010
PublicationTitle 中国肺癌杂志
PublicationTitleAlternate Chinese Journal of Lung Cancer
PublicationTitle_FL Chinese Journal of Lung Cancer
PublicationYear 2013
Publisher 新疆医科大学附属肿瘤医院肺内一科, 新疆,830011
Publisher_xml – name: 新疆医科大学附属肿瘤医院肺内一科, 新疆,830011
SSID ssj0062934
ssib002262905
ssib044765436
ssib001103766
ssib038074678
ssib051369142
Score 1.9561254
Snippet 背景与目的小分子酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）对于表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变的肺癌患者显示出良好的...
背景与目的 小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)对于表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的肺癌患者显示出良好的治疗...
SourceID wanfang
chongqing
SourceType Aggregation Database
Publisher
StartPage 303
SubjectTerms 疗效
肺肿瘤
血清
表皮生长因子受体
酪氨酸激酶抑制剂
Title 晚期NSCLC患者血清EGFR基因突变状态的测定及意义
URI http://lib.cqvip.com/qk/91098A/201306/46182813.html
https://d.wanfangdata.com.cn/periodical/zgfazz201306006
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: KQ8
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DOA
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DIK
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib044765436
  issn: 1009-3419
  databaseCode: M~E
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: East & South Asia Database
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BVBZV
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eastsouthasia
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BENPR
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1NT9RAdIKQEC_GzwgqIdE5LrYz7XTmZNpuV2KEGMSE26bttnBa_IDLnsDAQThwVTRB482DN436e9zCz_C9t6VbCPErIZu3b97M-9rpex1m3jB2J81N3rGyuKF17uJqFUyp3FYNpYWdWlbsCoVnh-fm1ewT58GSuzRybre2a2l9LZlJe2eeK_kfrwIO_IqnZP_Bs9WggAAY_Auf4GH4_Csf80hxY7jxCQi5ac0_Dh-G-E0L7kseadzJoF0EfBthaAoA6Ub3Wws8cqELD3wCAu5Ds8d9H7JLxOgWNxox2ueBokEtavKQo3ZoLCALkNiPSAzqpUkeIAA4cnhg-OD-nuMkmJAgULPkGzRJUEGSeKiRJh1ME5FAE4AkVbzkkeE-_IUkWsQDMWwB9pqE1tiiTb0lCElBhbqY4ESfJjfuyT7lOsjgACv9Zkkg6Ew2AkAr6hryICCrAZKs5jsII9DkvkJhUR-HJLC5iY5VbdE4GumH4xCxL2rmcJEROpBMpq0hL5gbZ8gkQi0xAa8FG_zHFNbTOxGNVG3W1UOLtGQtS5GDu4JPB0AsH0kBEBnMVAxwC6OkOrWnyo5TItNbzuNeD0ksReXrxwQubo2ysSCaf7QwzK7xTGn9bV8oYYbhAq8ugLBbPc4dx8ODyxW9a0tlbKeq7gadB5s-jqUcZ7dLFe7-RgEsgrKy2l1-BqkdnbTr5nF3uZYULl5kF8q3uWl_MDUvsZHeymU2PlfuV7nC7hVv9ot3BzQri5cfjza2jz5sFN-2cfb1D370374__LTZ33t9uPO12Ng83N8qvuz2P-_393aKrb2f319dZYutaDGcbZRXljRSV6tG7sAj0clkojuZk8aZNpjf23YSQzB3cyHSTBmnA-_wSSp1Btl6JwcLKdXJXNHxpLzGRrur3ew6m86FiaXOVS5Tz8k6uTaJsVIv0a6VpokyE2yyMkP76aAyTRt4aaFtOcGmS7u0y8fVi_YpL0_-meQGOy_o8hdccLzJRteer2e3IAVfS6bKn8YULWH9AiGbpK4
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%99%9A%E6%9C%9FNSCLC%E6%82%A3%E8%80%85%E8%A1%80%E6%B8%85EGFR%E5%9F%BA%E5%9B%A0%E7%AA%81%E5%8F%98%E7%8A%B6%E6%80%81%E7%9A%84%E6%B5%8B%E5%AE%9A%E5%8F%8A%E6%84%8F%E4%B9%89&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%82%BA%E7%99%8C%E6%9D%82%E5%BF%97&rft.au=%E9%A9%AC%E7%8E%B2&rft.au=%E5%88%98%E8%8E%89&rft.au=%E5%BC%A0%E6%B6%9B&rft.au=%E5%8D%95%E8%8E%89&rft.date=2013&rft.pub=%E6%96%B0%E7%96%86%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%82%BA%E5%86%85%E4%B8%80%E7%A7%91%2C+%E6%96%B0%E7%96%86%2C830011&rft.issn=1009-3419&rft.volume=16&rft.issue=6&rft.spage=303&rft.epage=307&rft_id=info:doi/10.3779%2Fj.issn.1009-3419.2013.06.06&rft.externalDocID=zgfazz201306006
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91098A%2F91098A.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgfazz%2Fzgfazz.jpg